Literature DB >> 29868973

Conservative versus liberal oxygenation targets in critically ill children: the randomised multiple-centre pilot Oxy-PICU trial.

Mark J Peters1,2, Gareth A L Jones3,4, Daisy Wiley5, Jerome Wulff5, Padmanabhan Ramnarayan6,7, Samiran Ray4, David Inwald7, Michael Grocott8, Michael Griksaitis9,10, John Pappachan9,10, Lauran O'Neill4, Simon Eaton11, Paul R Mouncey5, David A Harrison5, Kathryn M Rowan5.   

Abstract

BACKGROUND: Oxygen saturation monitoring for children receiving respiratory support is standard worldwide. No randomised clinical trials have compared peripheral oxygen saturation (SpO2) targets for critically ill children. The harm of interventions to raise SpO2 to > 94% may exceed their benefits.
METHODS: We undertook an open, parallel-group randomised trial of children > 38 weeks completed gestation and < 16 years of age receiving invasive or non-invasive respiratory support and supplemental oxygen who were admitted urgently to one of three paediatric intensive care units. A 'research without prior consent' approach was employed. Children were randomly assigned to a liberal oxygenation group (SpO2 targets > 94%) or a conservative oxygenation group (SpO2 = 88-92% inclusive). Outcomes were measures of feasibility: recruitment rate, protocol adherence and acceptability, between-group separation of SpO2 and safety. The Oxy-PICU trial was registered before recruitment: ClinicalTrials.gov identifier NCT03040570.
RESULTS: A total of 159 children met the inclusion criteria, of whom 119 (75%) were randomised between April and July 2017, representing a rate of 10 patients per month per site. The mean time to randomisation from first contact with an intensive care team was 1.9 (SD 2.2) h. Consent to continue in the study was obtained in 107 cases (90%); the children's parents/legal representatives were supportive of the consent process. The median (interquartile range, IQR) of time-weighted individual mean SpO2 was 94.9% (92.6-97.1) in the conservative oxygenation group and 97.5% (96.2-98.4) in the liberal group [difference 2.7%, 95% confidence interval (95% CI) 1.3-4.0%, p < 0.001]. Median (IQR) time-weighted individual mean FiO2 was 0.28 (0.24-0.37) in the conservative group and 0.37 (0.30-0.42) in the liberal group (difference 0.08, 95% CI 0.03-0.13, p < 0.001). There were no significant between-group differences in length of stay, duration of organ support or mortality. Two prespecified serious adverse events (cardiac arrests) occurred, both in the liberal oxygenation group.
CONCLUSION: A definitive clinical trial of peripheral oxygen saturation targets is feasible in critically ill children.

Entities:  

Keywords:  Clinical trial; Oxygenation; PICU respiratory failure

Mesh:

Substances:

Year:  2018        PMID: 29868973     DOI: 10.1007/s00134-018-5232-7

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  27 in total

1.  Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial.

Authors:  Pierre Asfar; Frédérique Schortgen; Julie Boisramé-Helms; Julien Charpentier; Emmanuel Guérot; Bruno Megarbane; David Grimaldi; Fabien Grelon; Nadia Anguel; Sigismond Lasocki; Matthieu Henry-Lagarrigue; Frédéric Gonzalez; François Legay; Christophe Guitton; Maleka Schenck; Jean Marc Doise; Jérôme Devaquet; Thierry Van Der Linden; Delphine Chatellier; Jean Philippe Rigaud; Jean Dellamonica; Fabienne Tamion; Ferhat Meziani; Alain Mercat; Didier Dreyfuss; Valérie Seegers; Peter Radermacher
Journal:  Lancet Respir Med       Date:  2017-02-15       Impact factor: 30.700

2.  Understanding the benefits and harms of oxygen therapy.

Authors:  Pierre Asfar; Mervyn Singer; Peter Radermacher
Journal:  Intensive Care Med       Date:  2015-01-30       Impact factor: 17.440

3.  The Effects of Oxygen Therapy on Myocardial Salvage in ST Elevation Myocardial Infarction Treated with Acute Percutaneous Coronary Intervention: The Supplemental Oxygen in Catheterized Coronary Emergency Reperfusion (SOCCER) Study.

Authors:  Ardavan Khoshnood; Marcus Carlsson; Mahin Akbarzadeh; Pallonji Bhiladvala; Anders Roijer; Stefan Bodetoft; Peter Höglund; David Zughaft; Lizbet Todorova; David Erlinge; Ulf Ekelund
Journal:  Cardiology       Date:  2015-05-20       Impact factor: 1.869

Review 4.  Adaptive Designs for Clinical Trials.

Authors:  Deepak L Bhatt; Cyrus Mehta
Journal:  N Engl J Med       Date:  2016-07-07       Impact factor: 91.245

5.  Effect of Conservative vs Conventional Oxygen Therapy on Mortality Among Patients in an Intensive Care Unit: The Oxygen-ICU Randomized Clinical Trial.

Authors:  Massimo Girardis; Stefano Busani; Elisa Damiani; Abele Donati; Laura Rinaldi; Andrea Marudi; Andrea Morelli; Massimo Antonelli; Mervyn Singer
Journal:  JAMA       Date:  2016-10-18       Impact factor: 56.272

6.  Relationship between supranormal oxygen tension and outcome after resuscitation from cardiac arrest.

Authors:  J Hope Kilgannon; Alan E Jones; Joseph E Parrillo; R Phillip Dellinger; Barry Milcarek; Krystal Hunter; Nathan I Shapiro; Stephen Trzeciak
Journal:  Circulation       Date:  2011-05-23       Impact factor: 29.690

7.  The association between hyperoxia and patient outcomes after cardiac arrest: analysis of a high-resolution database.

Authors:  Jonathan Elmer; Michael Scutella; Raghevesh Pullalarevu; Bo Wang; Nishit Vaghasia; Stephen Trzeciak; Bedda L Rosario-Rivera; Francis X Guyette; Jon C Rittenberger; Cameron Dezfulian
Journal:  Intensive Care Med       Date:  2014-12-04       Impact factor: 17.440

8.  Hyperoxia Is Associated With Poor Outcomes in Pediatric Cardiac Patients Supported on Venoarterial Extracorporeal Membrane Oxygenation.

Authors:  Nathaniel R Sznycer-Taub; Ray Lowery; Sunkyung Yu; Sonal T Owens; Jennifer C Hirsch-Romano; Gabe E Owens
Journal:  Pediatr Crit Care Med       Date:  2016-04       Impact factor: 3.624

9.  Target ranges of oxygen saturation in extremely preterm infants.

Authors:  Waldemar A Carlo; Neil N Finer; Michele C Walsh; Wade Rich; Marie G Gantz; Abbot R Laptook; Bradley A Yoder; Roger G Faix; Abhik Das; W Kenneth Poole; Kurt Schibler; Nancy S Newman; Namasivayam Ambalavanan; Ivan D Frantz; Anthony J Piazza; Pablo J Sánchez; Brenda H Morris; Nirupama Laroia; Dale L Phelps; Brenda B Poindexter; C Michael Cotten; Krisa P Van Meurs; Shahnaz Duara; Vivek Narendran; Beena G Sood; T Michael O'Shea; Edward F Bell; Richard A Ehrenkranz; Kristi L Watterberg; Rosemary D Higgins
Journal:  N Engl J Med       Date:  2010-05-16       Impact factor: 91.245

Review 10.  Bench-to-bedside review: the effects of hyperoxia during critical illness.

Authors:  Hendrik J F Helmerhorst; Marcus J Schultz; Peter H J van der Voort; Evert de Jonge; David J van Westerloo
Journal:  Crit Care       Date:  2015-08-17       Impact factor: 9.097

View more
  14 in total

1.  'Lumping or splitting' in paediatric acute respiratory distress syndrome (PARDS).

Authors:  Daniele De Luca; David A Harrison; Mark J Peters
Journal:  Intensive Care Med       Date:  2018-08-24       Impact factor: 17.440

2.  Focus on paediatrics 2018.

Authors:  Hari Krishnan Kanthimathinathan; M J Peters
Journal:  Intensive Care Med       Date:  2018-10-23       Impact factor: 17.440

3.  Focus on paediatrics.

Authors:  Katherine L Brown; Martin C J Kneyber
Journal:  Intensive Care Med       Date:  2019-08-05       Impact factor: 17.440

Review 4.  Clinical trials and future directions in pediatric acute respiratory distress syndrome.

Authors:  Veerajalandhar Allareddy; Ira M Cheifetz
Journal:  Ann Transl Med       Date:  2019-10

5.  A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients.

Authors:  Daniel S Martin; Margaret McNeil; Chris Brew-Graves; Helder Filipe; Ronan O'Driscoll; Jia Liu Stevens; Rachel Burnish; Andrew F Cumpstey; Norman R Williams; Michael G Mythen; Michael Pw Grocott
Journal:  J Intensive Care Soc       Date:  2021-04-08

6.  Perceptions of Hyperoxemia and Conservative Oxygen Therapy in the Management of Acute Respiratory Failure.

Authors:  Brett R Curtis; Kimberly J Rak; Aaron Richardson; Kelsey Linstrum; Jeremy M Kahn; Timothy D Girard
Journal:  Ann Am Thorac Soc       Date:  2021-08

7.  Excessive Oxygen Supplementation in the First Day of Mechanical Ventilation Is Associated With Multiple Organ Dysfunction and Death in Critically Ill Children.

Authors:  Daniel R Balcarcel; Bria M Coates; Grace Chong; L Nelson Sanchez-Pinto
Journal:  Pediatr Crit Care Med       Date:  2022-02-01       Impact factor: 3.624

8.  Permissive versus restrictive temperature thresholds in critically ill children with fever and infection: a multicentre randomized clinical pilot trial.

Authors:  Mark J Peters; Kerry Woolfall; Imran Khan; Elisabeth Deja; Paul R Mouncey; Jerome Wulff; Alexina Mason; Rachel S Agbeko; Elizabeth S Draper; Blaise Fenn; Doug W Gould; Abby Koelewyn; Nigel Klein; Christine Mackerness; Sian Martin; Lauran O'Neill; Samiran Ray; Padmanabhan Ramnarayan; Shane Tibby; Kentigern Thorburn; Lyvonne Tume; Jason Watkins; Paul Wellman; David A Harrison; Kathryn M Rowan
Journal:  Crit Care       Date:  2019-03-07       Impact factor: 9.097

9.  Association of Severe Hyperoxemia Events and Mortality Among Patients Admitted to a Pediatric Intensive Care Unit.

Authors:  Sriram Ramgopal; Cameron Dezfulian; Robert W Hickey; Alicia K Au; Shekhar Venkataraman; Robert S B Clark; Christopher M Horvat
Journal:  JAMA Netw Open       Date:  2019-08-02

10.  FIRST-line support for assistance in breathing in children (FIRST-ABC): a master protocol of two randomised trials to evaluate the non-inferiority of high-flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in paediatric critical care.

Authors:  Alvin Richards-Belle; Peter Davis; Laura Drikite; Richard Feltbower; Richard Grieve; David A Harrison; Julie Lester; Kevin P Morris; Paul R Mouncey; Mark J Peters; Kathryn M Rowan; Zia Sadique; Lyvonne N Tume; Padmanabhan Ramnarayan
Journal:  BMJ Open       Date:  2020-08-04       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.